To determine the relationship between CTAB and survival, we performed KM overall survival analyses on a retrospective cohort of 250 patients with NSCLC treated with anti-PD-1 immunotherapy (pembrolizumab) alone or in combination with chemotherapy (Table 2). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.